Cytosorbents (CTSO) Operating Leases (2018 - 2026)

Cytosorbents (CTSO) has 9 years of Operating Leases data on file, last reported at $11.8 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases fell 4.58% year-over-year to $11.8 million; the trailing twelve-month figure through Mar 2026 stood at $11.8 million (down 4.58% YoY), and the FY2025 full-year result was $11.9 million, down 4.35% from the prior year.
• Operating Leases for Q1 2026 stood at $11.8 million, down from $11.9 million in the prior quarter.
• Across five years, Operating Leases topped out at $13.5 million in Q2 2022 and bottomed at $11.8 million in Q1 2026.
• The 5-year median for Operating Leases is $12.9 million (2023), against an average of $12.7 million.
• The widest annual swing landed in 2022, when Operating Leases soared 2756.95%; it then retreated 6.57% in 2025.
• A 5-year view of Operating Leases shows it stood at $13.1 million in 2022, then dropped by 1.87% to $12.9 million in 2023, then slipped by 3.51% to $12.4 million in 2024, then dropped by 4.35% to $11.9 million in 2025, then dropped by 1.27% to $11.8 million in 2026.
• The last three Operating Leases figures came in at $11.8 million (Q1 2026), $11.9 million (Q4 2025), and $12.1 million (Q3 2025), per Business Quant data.

Peer Comparison